Famotidine-13C-d3
目录号 : GC47331
A neuropeptide with diverse biological activities
Cas No.:2744683-81-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Famotidine-13C-d3 is intended for use as an internal standard for the quantification of famotidine by GC- or LC-MS. Famotidine is a histamine H2 receptor antagonist with a Ki value of 12 nM in fractionated guinea pig cerebral cortex membranes.1 It is selective for H2 over H1 and muscarinic receptors (Kis = 4 and 28 µM, respectively, in bovine cerebral cortex).2 Famotidine inhibits histamine-induced acid secretion in isolated canine parietal cells (IC50 = 0.6 µM).3 It also suppresses histamine-induced gastric acid secretion in dogs when administered orally and in anesthetized rats when administered intraduodenally (ID50s = 10 and 400 µg/kg, respectively).3 Formulations containing famotidine have been used in the treatment of ulcers, gastroesophageal reflux disease (GERD), and heartburn, as well as to decrease the risk of gastrointestinal toxicity associated with non-steroidal anti-inflammatory drugs (NSAIDs).
1.Gajtkowski, G.A., Norris, D.B., Rising, T.J., et al.Specific binding of 3H-tiotidine to histamine H2 receptors in guinea pig cerebral cortexNature304(5921)65-67(1983) 2.Kubo, N., Shirakawa, S., Kuno, T., et al.Antimuscarinic effects of antihistamines: Quantitative evaluation by receptor-binding assayJpn. J. Pharmacol.43(3)277-282(1987) 3.Nagaya, H., Inatomi, N., and Satoh, H.Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogsJpn. J. Pharmacol.55(4)425-436(1991)
| Cas No. | 2744683-81-4 | SDF | |
| Canonical SMILES | NS(N[13C](C([2H])C([2H])([2H])SCC1=CSC(NC(N)=N)=N1)=N)(=O)=O | ||
| 分子式 | C7[13C]H12D3N7O2S3 | 分子量 | 341.5 |
| 溶解度 | DMF: soluble,DMSO: soluble,Methanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9283 mL | 14.6413 mL | 29.2826 mL |
| 5 mM | 0.5857 mL | 2.9283 mL | 5.8565 mL |
| 10 mM | 0.2928 mL | 1.4641 mL | 2.9283 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。